Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
PAX6 gene therapy rescue of mouse small eye
FY 2012-13
Summary
While some illnesses, such as tuberculosis, are caused by a bacterial infection, others are inherited genetically and are caused by defects in our genes. Bacterial infections can be cured, usually by killing the bacteria that causes them, but no such cure exists for most genetic diseases. Instead, sometimes a special diet or particular medicine can reduce the symptoms, but the person lives with the disease for their entire life. One such disease is aniridia, which hinders eye development in the people affected by it, leaving them with poor vision from birth and blinding them by their mid-20s. Currently there are several treatments that help alleviate some of the symptoms of aniridia, but none of them can save the vision of a person with this disease. Gene therapy is a promising approach that attempts to cure these previously incurable diseases by providing functioning copies of the defective gene to the cells that need them. In Europe and in the United States, there have been breakthrough successes that have demonstrated the efficacy of the gene therapy approach. In most of these cases, the initial research began by testing the therapy in a mouse model, and we propose to do the same as we start developing a gene therapy for aniridia. Already a gene that causes 80% of the cases of aniridia in humans, PAX6, is known. Our research will involve testing how different viruses deliver PAX6 to any already established mouse model of aniridia. We will also explore how we can adjust the gene so that it is expressed in the right tissues and at the right levels to cure the disease in mice. Taking these first initial steps in mice will allow us to work out all of the necessary details needed before advancing towards a gene therapy in humans. By starting this project, we are working towards a gene therapy cure for aniridia in humans.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
280766
Name
Hickmott Jack
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
PAX6 gene therapy rescue of mouse small eye
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Aav2/9; Aniridia; Gene Therapy; Pax6
Abstract
While some illnesses, such as tuberculosis, are caused by a bacterial infection, others are inherited genetically and are caused by defects in our genes. Bacterial infections can be cured, usually by killing the bacteria that causes them, but no such cure exists for most genetic diseases. Instead, sometimes a special diet or particular medicine can reduce the symptoms, but the person lives with the disease for their entire life. One such disease is aniridia, which hinders eye development in the people affected by it, leaving them with poor vision from birth and blinding them by their mid-20s. Currently there are several treatments that help alleviate some of the symptoms of aniridia, but none of them can save the vision of a person with this disease. Gene therapy is a promising approach that attempts to cure these previously incurable diseases by providing functioning copies of the defective gene to the cells that need them. In Europe and in the United States, there have been breakthrough successes that have demonstrated the efficacy of the gene therapy approach. In most of these cases, the initial research began by testing the therapy in a mouse model, and we propose to do the same as we start developing a gene therapy for aniridia. Already a gene that causes 80% of the cases of aniridia in humans, PAX6, is known. Our research will involve testing how different viruses deliver PAX6 to any already established mouse model of aniridia. We will also explore how we can adjust the gene so that it is expressed in the right tissues and at the right levels to cure the disease in mice. Taking these first initial steps in mice will allow us to work out all of the necessary details needed before advancing towards a gene therapy in humans. By starting this project, we are working towards a gene therapy cure for aniridia in humans.
Competitiondate
201302
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hickmott, Jack
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~